Dupixent® (Dupilumab) exhibited superiority over Xolair® (Omalizumab) in chronic parathyroiditis with nasal polyps (CRSWNPs) in first-time phase 4 head asthma patients, which was presented for the first time.

Dupixent® (Dupilumab) exhibited superiority over Xolair® (Omalizumab) in chronic parathyroiditis with nasal polyps (CRSWNPs) in first-time phase 4 head asthma patients, which was presented for the first time.